← Karyopharm Therapeutics Inc. (KPTI) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Karyopharm Therapeutics Inc. (KPTI)
Pharmaceutical Preparations · market cap $39M · as of 2026-07-12
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-02 (est.)
Earnings
Pipeline
5
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Karyopharm Therapeutics (KPTI) is a small-cap pharma with 279 employees and a $234M market cap, anchored by selinexor — an XPO1 inhibitor with FDA approvals in multiple myeloma and DLBCL — now being evaluated across several hematologic malignancies and solid tumors. The company faces a compressed 12-month cash runway against a net debt position of $74.8M, with two high-importance Phase 3 selinexor readouts expected in August and December 2026 as existential near-term catalysts.
The catalyst path
- 2026-11-02 (est.)Earningsimp 5/10
- 2026-12-15 (est.)Phase 3 · Selinexor (combination therapy)imp 9/10
- 2027-06-15 (est.)Phase 2 · Selinexor 60 mgimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Selinexor 60 mg | Phase 2 | Myelofibrosis |
| Selinexor (combination therapy) | Phase 3 | Relapsed/Refractory Diffuse Large B-cell Lymphoma |
| KPT-8602 | Phase 2 | Relapsed/Refractory Multiple Myeloma (RRMM) |
| Selinexor 100 mg | Phase 2 | Non-Small Cell Lung Carcinoma (NSCLC) |
| Selinexor | Phase 3 | Multiple Myeloma, Refractory |
Price & technical context
3-month
-90.9%
6-month
-85.1%
12-month
-86.0%
52-wk range
$0.87–$10.67
vs 50-day MA
-64.2%
vs 200-day MA
-87.1%
Realized vol
159.8%
Max drawdown
-94.1%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for KPTI (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 5 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.